The FDA has approved the endothelin-receptor antagonist Letairis (ambrisentan) for the treatment of pulmonary arterial hypertension.
In clinical trials, the once-daily pill effectively delayed worsening of the condition.
The FDA notes that Letairis may cause birth defects and should not be used during pregnancy.
fda announcement
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment